February 3rd 2022
Clinical pearls regarding ways to integrate antibody-drug conjugates into treatment algorithms when managing patients with breast cancer.
January 28th 2022
Strategies that can be used to mitigate and manage adverse events associated with sacituzumab govitecan therapy for triple-negative breast cancer.
January 21st 2022
Strategies used to help monitor and manage T-DXd treatment-related adverse events.
Recommendations for starting a patient with HER2+ metastatic breast cancer on T-DXd after prior T-DM1 therapy.